These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34575401)

  • 1. PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates.
    Reddy MB; Bolger MB; Fraczkiewicz G; Del Frari L; Luo L; Lukacova V; Mitra A; Macwan JS; Mullin JM; Parrott N; Heikkinen AT
    Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine.
    Docci L; Umehara K; Krähenbühl S; Fowler S; Parrott N
    AAPS J; 2020 Oct; 22(6):128. PubMed ID: 33033903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK Modelling for Drugs Cleared by Non-CYP Enzymes: State-of-the-Art and Future Perspectives.
    Ozbey AC; Fowler S; Leys K; Annaert P; Umehara K; Parrott N
    Drug Metab Dispos; 2023 Oct; ():. PubMed ID: 37879848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling.
    Moreira FD; Tarozzo MM; Nardotto GH; Gonçalves JC; Schmidt S; de-Moraes NV
    Eur J Pharm Sci; 2022 Dec; 179():106309. PubMed ID: 36265816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5'-Diphosphate Glucuronosyltransferase.
    Ahmed AN; Rostami-Hodjegan A; Barber J; Al-Majdoub ZM
    Drug Metab Dispos; 2022 Aug; 50(8):1119-1125. PubMed ID: 35636771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat.
    Frechen S; Ince I; Dallmann A; Gerisch M; Jungmann NA; Becker C; Lobmeyer M; Trujillo ME; Xu S; Burghaus R; Meyer M
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):79-92. PubMed ID: 37794724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors.
    Liu SN; Lu JBL; Watson CJW; Lazarus P; Desta Z; Gufford BT
    Drug Metab Dispos; 2019 May; 47(5):535-544. PubMed ID: 30804050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.
    Heikkinen AT; Baneyx G; Caruso A; Parrott N
    Eur J Pharm Sci; 2012 Sep; 47(2):375-86. PubMed ID: 22759901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).
    Zhou J; Argikar UA; Miners JO
    Methods Mol Biol; 2021; 2342():301-338. PubMed ID: 34272700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.
    Komura H; Iwaki M
    Drug Metab Rev; 2011 Nov; 43(4):476-98. PubMed ID: 21859377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the potential role of intestinal first-pass metabolism for the prediction of drug-drug interactions: the role of PBPK modeling.
    Alqahtani S; Bukhari I; Albassam A; Alenazi M
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):625-634. PubMed ID: 29806951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics.
    Achour B; Russell MR; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2014 Apr; 42(4):500-10. PubMed ID: 24408517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equine uridine diphospho-glucuronosyltransferase 1A1, 2A1, 2B4, 2B31: cDNA cloning, expression and initial characterization of morphine metabolism.
    Hamamoto-Hardman BD; Baden RW; McKemie DS; Knych HK
    Vet Anaesth Analg; 2020 Nov; 47(6):763-772. PubMed ID: 32933848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
    Callegari E; Lin J; Tse S; Goosen TC; Sahasrabudhe V
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):127-136. PubMed ID: 33314761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender-dependent differences in uridine 5'-diphospho-glucuronosyltransferase have implications in metabolism and clearance of xenobiotics.
    Liu W; Kulkarni K; Hu M
    Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1555-69. PubMed ID: 24011176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast.
    Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M
    Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs).
    Zhou J; Miners JO
    Methods Mol Biol; 2014; 1113():203-28. PubMed ID: 24523115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes.
    Docci L; Klammers F; Ekiciler A; Molitor B; Umehara K; Walter I; Krähenbühl S; Parrott N; Fowler S
    AAPS J; 2020 Oct; 22(6):131. PubMed ID: 33051808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.